These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18332634)

  • 1. Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction.
    Chung AW; Booth AD; Rose C; Thompson CR; Levin A; van Breemen C
    J Vasc Res; 2008; 45(4):357-62. PubMed ID: 18332634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging is associated with increased matrix metalloproteinase-2 activity in the human aorta.
    McNulty M; Spiers P; McGovern E; Feely J
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):504-9. PubMed ID: 15831360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease.
    Chung AW; Yang HH; Sigrist MK; Brin G; Chum E; Gourlay WA; Levin A
    Cardiovasc Res; 2009 Dec; 84(3):494-504. PubMed ID: 19617223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature.
    Chung AW; Hsiang YN; Matzke LA; McManus BM; van Breemen C; Okon EB
    Circ Res; 2006 Jul; 99(2):140-8. PubMed ID: 16778129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease.
    Chung AW; Yang HH; Kim JM; Sigrist MK; Chum E; Gourlay WA; Levin A
    Circulation; 2009 Sep; 120(9):792-801. PubMed ID: 19687355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease.
    Nagano M; Fukami K; Yamagishi S; Ueda S; Kaida Y; Matsumoto T; Yoshimura J; Hazama T; Takamiya Y; Kusumoto T; Gohara S; Tanaka H; Adachi H; Okuda S
    Am J Nephrol; 2009; 29(2):109-15. PubMed ID: 18701818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of acute functional injury following percutaneous renal artery intervention.
    Davies MG; Saad WE; Peden EK; Mohiuddin IT; Naoum JJ; Lumsden AB
    Ann Vasc Surg; 2008 Nov; 22(6):783-9. PubMed ID: 18692990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A newly estimated glomerular filtration rate is independently associated with arterial stiffness in Japanese patients.
    Nakagawa N; Takahashi F; Chinda J; Kobayashi M; Hayashi Y; Abe M; Saijo Y; Kikuchi K; Hasebe N
    Hypertens Res; 2008 Feb; 31(2):193-201. PubMed ID: 18360037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate.
    Cirillo M; Lanti MP; Menotti A; Laurenzi M; Mancini M; Zanchetti A; De Santo NG
    Arch Intern Med; 2008 Mar; 168(6):617-24. PubMed ID: 18362254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early identification of kidney disease by eGFR: what is the prevalence of eGFR in the population?
    Cirillo M; Lombardi C; Chiricone D; Bilancio G; Marcarelli F; De Santo NG
    J Nephrol; 2008; 21 Suppl 13():S102-6. PubMed ID: 18446741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiorenal syndrome in ischemic renal disease (atherosclerotic renovascular hypertension)].
    Mukhin NA; Fomin VV; Moiseev SV; Shvetsov MIu; Kutyrina IM; Zaĭtsev AIu; Taronishvili OI
    Ter Arkh; 2008; 80(8):30-8. PubMed ID: 18807537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients.
    Chang HR; Kuo WH; Hsieh YS; Yang SF; Lin CC; Lee ML; Lian JD; Chu SC
    Transl Res; 2008 Apr; 151(4):217-23. PubMed ID: 18355769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.
    Martinez ML; Castro MM; Rizzi E; Fernandes K; Demacq C; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Sep; 591(1-3):224-30. PubMed ID: 18634778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension.
    Castro MM; Rizzi E; Rodrigues GJ; Ceron CS; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2009 May; 46(9):1298-307. PubMed ID: 19248829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).
    Yokoyama H; Sone H; Oishi M; Kawai K; Fukumoto Y; Kobayashi M;
    Nephrol Dial Transplant; 2009 Apr; 24(4):1212-9. PubMed ID: 18984626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent association of circulating resistin with glomerular filtration rate in the early stages of essential hypertension.
    Dimitriadis K; Tsioufis C; Selima M; Tsiachris D; Miliou A; Kasiakogias A; Andrikou E; Tousoulis D; Stefanadis C
    J Hum Hypertens; 2009 Oct; 23(10):668-73. PubMed ID: 19262583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and prevention of chronic kidney disease in Indonesia: initial community screening.
    Prodjosudjadi W; Suhardjono ; Suwitra K; Pranawa ; Widiana IG; Loekman JS; Nainggolan G; Prasanto H; Wijayanti Y; Dharmeizar ; Sja'bani M; Nasution MY; Basuki W; Aditiawardana ; Harris DC; Pugsley DJ;
    Nephrology (Carlton); 2009 Oct; 14(7):669-74. PubMed ID: 19796026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy.
    Van Linthout S; Seeland U; Riad A; Eckhardt O; Hohl M; Dhayat N; Richter U; Fischer JW; Böhm M; Pauschinger M; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2008 Jul; 103(4):319-27. PubMed ID: 18347835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
    Anavekar NS; Solomon SD; McMurray JJ; Maggioni A; Rouleau JL; Califf R; White H; Kober L; Velazquez E; Pfeffer MA
    Am J Cardiol; 2008 Apr; 101(7):925-9. PubMed ID: 18359309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.